Blood Test Detects Alzheimer's Before Symptoms Start

A simple blood test might soon detect Alzheimer's disease before memory problems even begin, giving patients a fighting chance at early treatment.

Researchers at The Scripps Research Institute analyzed blood samples from over 500 people and found something remarkable. Three proteins in our blood change shape as Alzheimer's develops, and these structural shifts appear before traditional markers show up.

The new test works differently than current methods. Instead of measuring protein amounts, it examines how these molecules fold and unfold in the bloodstream.

Scientists studied three groups: healthy adults, people with mild cognitive impairment, and Alzheimer's patients. Using machine learning, they identified three key proteins that transform as the disease progresses.

The first protein, C1QA, plays a role in immune signaling. The second, clusterin, helps fold proteins correctly and clear out amyloid buildup. The third, apolipoprotein B, transports fats through blood and maintains healthy blood vessels.

As Alzheimer's advanced, these proteins became less structurally "open" in the bloodstream. The shape changes proved more accurate at identifying disease stage than simply counting protein levels.

Why This Inspires

This discovery tackles a critical problem in Alzheimer's care: by the time most people get diagnosed, significant brain damage has already occurred. Current tests look for amyloid plaques and tau tangles in blood or spinal fluid, but these markers appear relatively late in the disease process.

The new approach recognizes that Alzheimer's likely involves a broader breakdown in proteostasis, our body's system for keeping proteins properly folded and removing damaged ones. This system weakens with age, making proteins more likely to misfold.

"Many neurodegenerative diseases are driven by changes in protein structure," explained senior author John Yates, a professor at Scripps. "The question was, are there structural changes in specific proteins that might be useful as predictive markers?"

The answer appears to be yes. If proteostasis fails in the brain, similar structural changes show up in blood proteins too.

The research team believes this multi-marker panel could enhance early detection and provide valuable insights for clinical trials. Better diagnostic tools mean researchers can test new treatments on people earlier in the disease process, when interventions might actually prevent damage rather than just slow it down.

For the 55 million people worldwide living with dementia, and the millions more who will develop it, earlier detection could mean more years of healthy, independent living with their loved ones.